FDA Approves Donanemab, Eli Lilly’s New Drug for Early Alzheimer’snews2024-07-02T18:58:44+00:00July 2nd, 2024|The New York Times|
FDA Advisory Panel Endorses Approval of Alzheimer’s Drug Made by Eli Lillynews2024-06-10T21:05:19+00:00June 10th, 2024|The New York Times|
Study Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’snews2024-05-06T16:19:15+00:00May 6th, 2024|The New York Times|
New Study Finds Alzheimer’s Drug Donanemab Can Modestly Slow Memory Declinenews2023-07-17T14:30:32+00:00July 17th, 2023|The New York Times|